| Gene symbol | GCGR | Synonyms | GGR, GL-R, MVAH | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | glucagon receptor | ||||
| GTO ID | GTC1560 |
| Trial ID | NCT02583919 |
| Disease | Type 2 Diabetes Mellitus |
| Altered gene | GCGR |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS-GCGRRx|Isis 449884 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin |
| Year | 2015 |
| Country | United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 449884-CS4 |
| Vector information | |||
|
|||
| Cohort1: Placebo | |||||||||||
|
|||||||||||
| Cohort2: ISIS-GCGRRx_dose level1 | |||||||||||
|
|||||||||||
| Cohort3: ISIS-GCGRRx_dose level2 | |||||||||||
|
|||||||||||